Moderna Shares Sink 9.30% Premarket on February 11, 2026 After FDA Refuses to File Flu Shot mRNA-1010

On February 11, 2026, Moderna's stock fell 9.30% in premarket trading to $38.09 after the FDA issued a refuse-to-file letter for its mRNA-1010 seasonal flu vaccine. The agency criticized the Phase 3 trial design for not using the best-available standard of care for older adults, while Moderna argued the decision conflicts with prior regulatory feedback and highlighted that the vaccine met trial objectives and is under review in other major markets.